Notably, YTHDC1 is vital for triple-negative breast cancer progression because it increases cancer cell survival and TGF-β-mediated EMT via SMAD3 to promote distant metastasis, highlighting the therapeutic potential of targeting the YTHDC1–m6A–SMAD3 axis [195]. Here, SMAD3 is linked to cancer.